Clinical Assessment of Fluticasone Propionate/ Salmeterol Xinafoate HFA MDI in 6-month to 4-year-old Japanese Patients With Bronchial Asthma
Phase of Trial: Phase IV
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 28 Mar 2017 Status changed from active, no longer recruiting to completed.
- 29 Jun 2016 Planned End Date changed from 1 Nov 2016 to 1 Oct 2016.
- 14 Apr 2016 Planned End Date changed from 1 Feb 2017 to 1 Nov 2016.